NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is on The StockGuru Leader Board today. The stock is up as much as 10.14% on Friday.
Volume traded – so far – as this release was issued intraday: 1,026,352
Join in on the Discussion about NPSP: http://members.stockguru.com/stocks/npsp/
About the Company:
NPS Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic products for gastrointestinal and endocrine disorders, and various medical needs. The companys primary clinical programs include two therapeutic peptides to restore or replace biological functions comprising GATTEX, a Phase 3 clinical trial product for short bowel syndrome; and Natpara, a recombinant human parathyroid hormone 1-84, which is in Phase 3 clinical development trials. It also develops NPSP790 and NPSP795 calcilytic compounds that are in Phase I trials for the treatment of rare endocrine disorders. The company has collaborative and license agreements with Amgen Inc., Janssen, GlaxoSmithKline, Kyowa Hakko Kirin, and Nycomed Danmark ApS. NPS Pharmaceuticals, Inc. was founded in 1986 and is based in Bedminster, New Jersey.
About the StockGuru Leader Board:
We watch for stocks moving up and creating a positive momentum in the market. We are not compensated for coverage.
Feel free to suggest a stock for coverage if you see it breaking out. Contact: email@example.com.